Abstract PD5-10: Pooled analysis of patients (pts) treated with 1st-line (1L) ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) studies: long-term progression-free survival (PFS)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Institut Gustave Roussy, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Hospital Clínic de Barcelona, Universitair Ziekenhuis Leuven, National Taiwan University Hospital, University of California, Los Angeles, European Institute of Oncology, The University of Texas at San Antonio Health Science Center, Memorial Sloan Kettering Cancer Center, National Cancer Centre Singapore, Novartis (United States), Novartis (Switzerland), Massachusetts General Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129312031